Business
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma
75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001)100% of patients who achieved 12 month event free survival achieved 2 year overall survivalNew York, New York--(Newsfile Corp. - October 10, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced statistically significant positive final...
About this update from Os Therapies Incorporated
[{"type":"list","items":[{"val":[{"type":"text","content":"75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001)","length":131,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"100% of patients who achieved 12 month event free survival achieved 2 year overall survival","length":91,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":222,"olType":false},{"type":"text","content":"New York, New York--(Newsfile Corp. - October 10, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced statistically significant positive final 2-year overall survival data from the Company's Phase 2b trial of off-the-shelf immunotherapy candidate OST-HER2 in the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma (the "Fully Resected Metastatic Osteosarcoma Trial"). 75% (27 out of 36 evaluable patients; 5 patients were lost to follow-up) of OST-HER2 treated patients achieved 2-year overall survival as measured from most recent pulmonary resection, compared with 40% of historical control patients1 (p < 0.0001) Subgroup analyses showed that 100% of patients who achieved 12-month Event Free Survival (EFS) achieved 2-year overall survival, whereas 59% of patients who did not achieve EFS achieved 2-year overall survival.","length":1032,"tagName":"p"},{"type":"text","content":""The overall survival data in this non-randomized OST-HER2 study is encouraging as the results show it was safe and well-tolerated," said Dr. Peter Anderson, pediatric oncologist at Cleveland Clinic Children's. "New treatments are needed for treating metastatic osteosarcoma, so I am hopeful this could become an option in the near future." Dr. Anderson is a scientific advisor for OS Therapies.","length":419,"tagName":"p"},{"type":"text","content":""The continued outperformance in overall survival of OST-HER2 when compared with historical control is exactly what we were hoping for when we started the Company in 2018," said Paul Romness, MPH, Chairman & CEO of OS Therapies. "We have had highly productive regulatory meetings with the United Kingdom's (UK) Medi...